Erythema Multiforme Major following SARS-CoV-2 vaccine

Alberto Maria Saibene | Andrea Alliata | Anna Teresa Cozzi | Alice Ottavi | Sofia Spagnolini | Carlotta Pipolo | Alberto Maccari | Giovanni Felisati

1 Otolaryngology Unit, Santi Paolo e Carlo Hospital, Department of Health Sciences, Università degli Studi di Milano, Milan, Italy
2 Department of Health Sciences, Università degli Studi di Milano, Milan, Italy

Received: 13 August 2021 | Revised: 16 September 2021 | Accepted: 27 September 2021
DOI: 10.1002/ccr3.4947

Introduction

Erythema multiforme (EM) is an immune-mediated skin reaction to infections or medications. Its oral cavity and mucosae-involving presentation (erythema multiforme major, EMM) represent a serious, occasionally life-threatening condition.1

EM may represent an adverse drug reaction (ADR) following vaccine administration, and it has been recently shown to sporadically follow SARS-CoV-2 vaccination.2 No EMM case, especially with prevalent oral involvement, has ever been documented to date following COVID-19 vaccines.

We report a case of a 58-year-old woman with oral and skin lesions due to SARS-CoV-2 vaccine-induced EMM.

Report of a Case

A 58-year-old woman presented to our emergency department reporting oral lesions, oral floor swelling, excruciating oral burning pain, dysphagia and odynophagia, and nocturnal fever the day after receiving the second dose of mRNA-1273 SARS-CoV-2 vaccine (Moderna Inc). She also reported cutaneous lesions on the right thigh and calf. She didn’t report any ADR after the first dose, while she did recall an analogous clinical picture after administration of metamizole and penicillin (respectively 27 and 16 years before). The patient was under treatment with oral sertraline, lorazepam, and atorvastatin, and she didn’t take any other drug during the previous month.

1 Otolaryngology Unit, Santi Paolo e Carlo Hospital, Department of Health Sciences, Università degli Studi di Milano, Milan, Italy
2 Department of Health Sciences, Università degli Studi di Milano, Milan, Italy

Funding information
The authors received no specific funding for this work and they have no financial disclosures to make.

Keywords
adverse drug reactions, Coronavirus infections, COVID-19, oral disease, vaccine

Abstract
Erythema multiforme major, an immune-mediated skin reaction to infections or medications with oral involvement, should be taken into account as a potential side effect of several vaccines, including SARS-CoV-2. Correct patient history collection allows prompt recognition and subsequent successful medical management with oral corticosteroids.
The patient presented to our emergency department on day 5 after the appearance of lesions, due to worsening of the clinical picture and the inability to hydrate and feed.

The otolaryngological evaluation confirmed an oral floor swelling accompanied by diffuse oral mucosal erosive lesions (Figure 1). The dermatologist identified two round erythematous-brownish target-like lesions (on the right thigh and calf) on unscathed skin, roughly 1 cm wide, without bubbles or detachment (Figure 2). There was no conjunctivitis or genital involvement. Laboratory tests identified only a moderate C-reactive protein increase (23.9 mg/L, normal range <10 mg/L) and the nasopharyngeal swab for SARS-CoV-2 proved negative. The infectious disease specialist requested serological testing for Chlamydia pneumoniae (IgG and IgM), Mycoplasma pneumoniae (IgG and IgM), T. pallidum, herpesviruses 1 and 2, hepatitis C, and hepatitis B. All serological testing was normal and safe for herpesvirus IgG (22.1 titration index, with positive values >1) and HBsAb resulting from mandatory vaccination (438 international units per liter, with positive values >10). Based on clinical appearance and medical history, a diagnosis of drug-related erythema multiforme was made, and IV methylprednisolone 1 mg/kg and fluid supplementation were started. IV morphine was required for pain management during the first 48 hours. A progressive improvement of the clinical picture with C-reactive protein normalization (9.3 mg/L) allowed for oral fluid intake on day 4, while oral feeding and IV steroids tapering began on day 5. The following day, the patient was dismissed on oral prednisone tapering, with almost complete resolution of the clinical picture. No recurrence was noted at the 1-month evaluation.

3 | DISCUSSION

To our knowledge, the authors present the first mRNA-vaccine-induced case of EMM. Although the relationship between EM and immunization procedures is already established, its link with recent mRNA vaccines is less clear. The pathophysiological mechanics might mimic the same immune response to SARS-CoV-2-mediated EM.

This report illustrates the diagnostic challenge posed by EMM, ie, its prevalently oral manifestation. In contrast with full-scale dermatological presentations (predominant both in mild EM cases, Stevens-Johnson syndrome, or toxic epidermal necrolysis—the latter two already described after SARS-CoV-2 immunization), oral lesions and symptoms might be also suggestive of fungal or viral infection.
infections. Mycoplasma pneumoniae-induced rash and mucositis might share the presentation with EMM, although often in younger patients, usually in their first or second decade. In the presented case, serological information allowed to rule out M. pneumoniae infection. It has to be noted also that the differential diagnosis between Stevens-Johnson syndrome and EMM might represent a clinical issue. Histological evaluation of skin lesions, which bear different features in EMM and Stevens-Johnson syndrome might represent an additional tool. In this specific case, the dermatologist considered the EMM diagnosis consistent with the clinical features and therefore decided not to perform any biopsy on the few skin lesions that appeared on the patient.

Dermatological manifestations can be mild or subtle and, unless the patient’s drug and personal history hint at an immune-mediated reaction, the corticosteroid treatment might get delayed.

Although EMM is a known vaccine ADR, the exceptional pandemic circumstances turned the spotlight back on potential vaccine risks, which have been long known and adequately managed in a large number of patients. ADRs to new mRNA vaccines have been therefore widely covered by the media and often speculatively manipulated into sensational claims, impacting negatively on vaccine public acceptance. The prompt recognition of infrequent ADRs such as EMM represents the most suitable tool to improve patients’ outcomes and trust toward healthcare providers.

ACKNOWLEDGMENTS
None.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
Alberto Maria Saibene and Andrea Alliata finalized the paper and wrote the final version. Anna Teresa Cozzi, Alice Ottavi, and Sofia Spagnolini drafted the paper. Carlotta Pipolo performed the clinical evaluations and prepared the images. Alberto Maccari and Giovanni Felisati acted as senior consultants for this paper.

CONSENT
The authors confirm that patient consent has been signed and collected in accordance with the journal’s patient consent policy.

DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

ORCID
Alberto Maria Saibene https://orcid.org/0000-0003-1457-6871

REFERENCES
1. Trayes KP, Love G, Studdiford JS. Erythema multiforme: recognition and management. Am Fam Physician. 2019;100(2):82-88.
2. Su JR, Haber P, Ng CS, et al. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999–2017. Vaccine. 2020;38(7):1746-1752.
3. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55.
4. Dash S, Sirkha CS, Mishra S, Viswan P. COVID-19 vaccine-induced Stevens–Johnson syndrome. Clin and Exp Dermatol. 2021;1-3. http://dx.doi.org/10.1111/ced.14784
5. Norton SA. Diagnosing mycoplasma pneumoniae-induced rash and mucositis (MIRM) in the emergency room. J Am Acad Dermatol. 2015;73(2):e67. https://doi.org/10.1016/j.jaad.2015.03.060
6. Watanabe R, Watanabe H, Sotozono C, Kokaze A, Iijima M. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Eur J Dermatol. 2011;21:889-894.
7. Szilagyi PG, Thomas K, Shah MD, et al. National Trends in the US Public’s Likelihood of Getting a COVID-19 Vaccine-April 1 to December 8, 2020. JAMA. 2020;325(4):396-398.
8. Saibene AM, Allevi F, Biglioli F, Felisati G. Role and management of a head and neck department during the COVID-19 outbreak in Lombardy. Otolaryngol Head Neck Surg. 2020;162(6):795-796.
9. Szapary AS, Cooperman A, Shah M, et al. Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IPOS and CEORL-HNS joint clinical consensus statement. Eur Arch Oto-Rhino-Laryngol. 2021;278(10):4091-4099. https://doi.org/10.1007/s00405-021-06794-6

How to cite this article: Saibene AM, Alliata A, Cozzi AT, et al. Erythema Multiforme Major following SARS-CoV-2 vaccine. Clin Case Rep. 2021;9:e04947. https://doi.org/10.1002/ccr3.4947